Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1757-6512
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa ; volume:7 ; number:1 ; day:27 ; month:8 ; year:2016 ; pages:1-15 ; date:12.2016
Stem cell research & therapy ; 7, Heft 1 (27.8.2016), 1-15, 12.2016
- Creator
-
Alexeev, Vitali
- Contributor
-
Donahue, Adele
Uitto, Jouni
Igoucheva, Olga
SpringerLink (Online service)
- DOI
-
10.1186/s13287-016-0388-y
- URN
-
urn:nbn:de:1111-20160926905
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Alexeev, Vitali
- Donahue, Adele
- Uitto, Jouni
- Igoucheva, Olga
- SpringerLink (Online service)
Other Objects (12)
STAT3 targeting in dystrophic epidermolysis bullosa
Dystrophic epidermolysis bullosa - from biochemistry to interventions
Mesenchymal stromal cell therapy for dystrophic epidermolysis bullosa
Biomechanics and epidermal barrier disruption in dystrophic epidermolysis bullosa
Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Pain in recessive dystrophic epidermolysis bullosa (RDEB): findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES)
Splicing modulation via antisense oligonucleotides in recessive dystrophic epidermolysis bullosa
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa
Recessive dystrophic epidermolysis bullosa caused by a novel COL7A1 variant with isodisomy
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
STAT3 targeting in dystrophic epidermolysis bullosa
Dystrophic epidermolysis bullosa - from biochemistry to interventions
Mesenchymal stromal cell therapy for dystrophic epidermolysis bullosa
Biomechanics and epidermal barrier disruption in dystrophic epidermolysis bullosa
Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Pain in recessive dystrophic epidermolysis bullosa (RDEB): findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES)
Splicing modulation via antisense oligonucleotides in recessive dystrophic epidermolysis bullosa
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa
Recessive dystrophic epidermolysis bullosa caused by a novel COL7A1 variant with isodisomy
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
STAT3 targeting in dystrophic epidermolysis bullosa
Dystrophic epidermolysis bullosa - from biochemistry to interventions
Mesenchymal stromal cell therapy for dystrophic epidermolysis bullosa
Biomechanics and epidermal barrier disruption in dystrophic epidermolysis bullosa
Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Pain in recessive dystrophic epidermolysis bullosa (RDEB): findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES)
Splicing modulation via antisense oligonucleotides in recessive dystrophic epidermolysis bullosa
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa
Recessive dystrophic epidermolysis bullosa caused by a novel COL7A1 variant with isodisomy